Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

NCT07659574 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

360

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: UBT251 Injection 2.0 mg
DRUG: UBT251 Injection 4.0 mg
DRUG: UBT251 Injection 6.0 mg
DRUG: UBT251 Injection Placebo 2.0 mg
DRUG: UBT251 Injection Placebo 4.0 mg
DRUG: UBT251 Injection Placebo 6.0 mg

Sponsor

The United Bio-Technology (Hengqin) Co., Ltd.